If any controlled substance appears in the listed bulk database, please ignore it, as we do not supply or offer controlled substances.
Apixaban Methyl Ester Impurity
100% accuracy
of data
24/7 scientific
support
0% tolerance in
quality of product

Stock Locations

  • New Jersey, USA
  • Czech Republic, EU
  • Mumbai, India

* Stock subject to availability.

Documentation

Download MSDS

Download Sample COA

Includes: HPLC, MASS/LC-MS, 1H NMR, FT-IR, Potency, Structure Elucidation Report (SER), and additional analytical data depending on the product.

1074365-84-6Apixaban Methyl Ester Impurity

● In Stock

Catalogue No.:VL3170007
CAS No.:1074365-84-6
Mol. Formula:C26H26N4O5
Mol. Weight:474.51 g/mol

Additional information on CAS 1074365-84-6

Parent drug

Apixaban

IUPAC Name

4, 5, 6, 7-Tetrahydro-1-(4-methoxyphenyl)-7-oxo-6-[4-(2-oxo-1-piperidinyl) phenyl]-1H-pyrazolo[3, 4-c]pyridine-3-carboxylic acid methyl ester

Pharmacopeial Synonyms

Apixaban Related Compound E

Other Synonyms

Methyl 1-(4-methoxyphenyl)-7-oxo-6-[4-(2-oxopiperidin-1-yl)phenyl]-4,5,6,7-tetrahydro-1Hpyrazolo[3,4-c]pyridine-3-carboxylate

Smiles

O=C(C1=NN(C2=CC=C(OC)C=C2)C3=C1CCN(C4=CC=C(N5C(CCCC5)=O)C=C4)C3=O)OC

InChI

InChI=1S/C26H26N4O5/c1-34-20-12-10-19(11-13-20)30-24-21(23(27-30)26(33)35-2)14-16-29(25(24)32)18-8-6-17(7-9-18)28-15-4-3-5-22(28)31/h6-13H,3-5,14-16H2,1-2H3

Description

Apixaban Methyl Ester Impurity, also known as Apixaban Related Compound E, in various pharmacopoeias, is a highly characterized standard. It meets strict regulatory requirements set by USP, EMA, JP, and BP, making it a crucial component in Abbreviated New Drug Applications (ANDA), New Drug Applications (NDA), and the commercial production of Apixaban. Apixaban Methyl Ester Impurity (CAS No: 1074365-84-6) or 4,5,6,7-Tetrahydro-1-(4-methoxyphenyl)-7-oxo-6-[4-(2-oxo-1-piperidinyl) phenyl]-1H-pyrazolo[3,4-c]pyridine-3-carboxylic acid methyl ester is a pyrazole derivative, it acts as Inhibition of factor Xa leads to decreased conversion of factor II to IIa, resulting in decreased thrombin generation and used in the treatment and prevent strokes or blood clots.

References

Hurst, Katherine, et al. “Quick Reference Guide to Apixaban.” Vascular Health and Risk Management, vol. Volume 13, July 2017, pp. 263–267, 10.2147/vhrm.s121944.

Request a Quote

"*" indicates required fields

This field is for validation purposes and should be left unchanged.
This field is hidden when viewing the form
Products quotation
Name
Url
 
This field is hidden when viewing the form
This field is hidden when viewing the form